Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2025 10:11 ET | Source: NovelMed Therapeutics Inc

United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin

--- The United States FDA Approves the Initiation for Phase II Efficacy Trial in Dermatomyositis (DM) Patients: A Skin & Muscle Disorder DM is an immune-mediated myopathy characterized by...
November 11, 2019 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile...
October 22, 2018 08:00 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

Lenabasum is a first-in-class novel, synthetic oral cannabinoid designed to treat rare, serious autoimmune diseasesFavorable safety and tolerability profiles maintained with long-term chronic...
June 13, 2018 09:29 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018

Multiple key efficacy outcomes further improved in open-label extensions of systemic sclerosis (SSc) and dermatomyositis (DM) Phase 2 studies Lenabasum continues to demonstrate a favorable safety...